Syngene's 7-phase integrated CMC strategy helps expedite IND/IMPD filings and FIH studies.
Transformative innovation in the pharmaceutical industry has resulted in an explosion in the types of novel modalities and therapies.
The world of drug discovery and development is rife with new approaches within immunotherapy, personalized vaccines, microbiome therapies, and CRISPR-based therapies to provide novel treatments and cures for a wide range of diseases. Even though progress is being made in these areas, more than 90 % of the drugs currently available on the worldwide therapeutics market are small molecules based.
DOWNLOAD NOW TO READ MORE >>>>